The prevalence of NASH in global populations continues to expand in conjunction with the ongoing obesity and diabetes epidemic. Over the next decade, the disease is projected to become the leading indication for a liver transplant. With no current approved drug treatment interest from the pharmaceutical industry, efforts by regulatory authorities and investigators to facilitate the development of new therapies that decrease the severity of NASH remain very strong, despite the high rates of attrition seen within pipelines to date. This webinar will focus on the ability of digital technologies, including magnetic resonance imaging (MRI), magnetic resonance elastography (MRE), and whole slide imaging (WSI), to address some of these challenges. It will illustrate the ability of MRI and MRE to provide timely, high-quality, non-invasive solutions to enrolment and on the power of WSI to facilitate rapid complex workflows that assure consistent, high-quality assessments of primary efficacy endpoints by enabling expert histopathologists to interact remotely and in real-time.
1. Identify challenges in NASH clinical trials.
2. Illustrate how digital technologies like MRI and MRE provide timely, high quality non-invasive solutions to NASH clinical trial enrollment.
3. Detail the power of whole slide imaging to facilitate rapid complex workflows In NASH clinical trials.